Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges
Authors:
Open Access
- 1 January 2017
- journal article
- review article
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-18
Abstract
Recombinant immunotoxins (RITs) refer to a group of recombinant protein-based therapeutics, which consists of two components: an antibody variable fragment or a specific ligand that allows RITs to bind specifically to target cells and an engineered toxin fragment that kills the target cells upon internalization. To date, over 1,000 RITs have been generated and significant success has been achieved in the therapy of hematological malignancies. However, the immunogenicity and off-target toxicities of RITs remain as significant barriers for their application to solid tumor therapy. A group of RITs have also been generated for the treatment of glioblastoma multiforme, and some have demonstrated evidence of tumor response and an acceptable profile of toxicity and safety in early clinical trials. Different from other solid tumors, how to efficiently deliver the RITs to intracranial tumors is more critical and needs to be solved urgently. In this article, we first review the design and expression of RITs, then summarize the key findings in the preclinical and clinical development of RIT therapy of glioblastoma multiforme, and lastly discuss the specific issues that still remain to forward RIT therapy to clinical practice.Keywords
Funding Information
- NIDCR (1R15DE025138-01, 1R25DE025778-01, NIH/NCRR/RCMI/4, G12 RR003048, 81401867)
- NIDCR (1R15DE025138-01, 1R25DE025778-01, NIH/NCRR/RCMI/4, G12 RR003048, 81401867)
- Howard University (1R15DE025138-01, 1R25DE025778-01, NIH/NCRR/RCMI/4, G12 RR003048, 81401867)
- Howard University (1R15DE025138-01, 1R25DE025778-01, NIH/NCRR/RCMI/4, G12 RR003048, 81401867)
- National Natural Science Foundation of China (1R15DE025138-01, 1R25DE025778-01, NIH/NCRR/RCMI/4, G12 RR003048, 81401867)
This publication has 178 references indexed in Scilit:
- An Anti‐PSMA Bivalent Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Imaging and TherapyAdvanced Healthcare Materials, 2012
- Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomasNuclear Medicine and Biology, 2010
- A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculatureJournal of Neuro-Oncology, 2010
- Antibody Vectors for ImagingSeminars in Nuclear Medicine, 2010
- Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1Journal of Neuro-Oncology, 2009
- Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activityBritish Journal of Cancer, 2009
- Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant gliomaSeminars in Immunology, 2008
- EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cellsCancer Immunology, Immunotherapy, 2007
- A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptorsProceedings of the National Academy of Sciences, 2007
- Immunotoxin therapy of cancerNature Reviews Cancer, 2006